Overview

Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)

Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effect of maraviroc therapy in obese insulin resistant subjects on: 1. Plasma triglyceride concentration 2. Plasma HDL-cholesterol and LDL-cholesterol concentrations 3. Plasma markers of cardiometabolic risk and inflammation
Phase:
Phase 1
Details
Lead Sponsor:
Washington University School of Medicine
Collaborator:
Pfizer
Treatments:
Maraviroc